Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

Basit Öğe Kaydı
dc.contributor.authorSoroush, Alborz
dc.contributor.authorShahhosseini, Reza
dc.contributor.authorGhavamikia, Nima
dc.contributor.authorHjazi, Ahmed
dc.contributor.authorRoudaki, Shahrzad
dc.contributor.authorKhalatbariLimaki, Mahdi
dc.contributor.authorMirbolouk, Mahtab
dc.contributor.authorPakmehr, SeyedAbbas
dc.contributor.authorKarimi, Parvin
dc.date.accessioned2024-06-27T05:15:40Z
dc.date.available2024-06-27T05:15:40Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi
dc.description.abstractThe heterogeneity of the solid tumor microenvironment (TME) impairs the therapeutic efficacy of standard therapies and also reduces the infiltration of antitumor immune cells, all of which lead to tumor progression and invasion. In addition, self-renewing cancer stem cells (CSCs) support tumor dormancy, drug resistance, and recurrence, all of which might pose challenges to the eradication of malignant tumor masses with current therapies. Natural forms of oncolytic viruses (OVs) or engineered OVs are known for their potential to directly target and kill tumor cells or indirectly eradicate tumor cells by involving antitumor immune responses, including enhancement of infiltrating antitumor immune cells, induction of immunogenic cell death, and reprogramming of cold TME to an immune-sensitive hot state. More importantly, OVs can target stemness factors that promote tumor progression, which subsequently enhances the efficacy of immunotherapies targeting solid tumors, particularly the CSC subpopulation. Herein, we describe the role of CSCs in tumor heterogeneity and resistance and then highlight the potential and remaining challenges of immunotherapies targeting CSCs. We then review the potential of OVs to improve tumor immunogenicity and target CSCs and finally summarize the challenges within the therapeutic application of OVs in preclinical and clinical trials.
dc.description.sponsorshipPrince Sattam bin Abdulaziz Universityen_US
dc.identifier.citationSoroush, A., Shahhosseini, R., Ghavamikia, N., Hjazi, A., Roudaki, S., KhalatbariLimaki, M. ... Karimi, P. (2024). Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells. Cell Biochemistry and Function, 42(4). http://dx.doi.org/10.1002/cbf.4055
dc.identifier.doi10.1002/cbf.4055
dc.identifier.issn0263-6484
dc.identifier.issn1099-0844
dc.identifier.issue4
dc.identifier.pmid38856033
dc.identifier.scopus2-s2.0-85195510452
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1002/cbf.4055
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12652
dc.identifier.volume42
dc.identifier.wos001241756700001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorShahhosseini, Reza
dc.language.isoen
dc.relation.ecinfo:eu-repo/grantAgreement/PSAU/2023/R/1445
dc.relation.ispartofCell Biochemistry and Functionen_US
dc.relation.publicationcategoryDiÄŸer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCancer Stemness
dc.subjectDrug Resistance
dc.subjectImmunotherapy
dc.subjectOncolytic Viruses
dc.subjectTumor Microenvironment
dc.titleImprovement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
Shahhosseini-Reza-2024.pdf
Boyut:
1.67 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu